Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $158.69

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received a consensus rating of “Buy” from the seventeen ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $158.6875.

A number of research firms have weighed in on PVLA. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Truist Financial upped their price objective on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Stifel Nicolaus raised their price objective on Palvella Therapeutics from $87.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, November 24th. Cantor Fitzgerald lifted their target price on Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Finally, Canaccord Genuity Group increased their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $81.54 on Friday. The firm’s 50 day moving average price is $93.27 and its 200-day moving average price is $76.04. Palvella Therapeutics has a 52-week low of $17.31 and a 52-week high of $114.69. The company has a market cap of $965.43 million, a PE ratio of -31.00 and a beta of -0.16.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders have sold a total of 12,906 shares of company stock worth $1,205,980 over the last three months. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

A number of institutional investors have recently made changes to their positions in PVLA. Group One Trading LLC increased its position in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares in the last quarter. Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics during the third quarter worth about $28,000. Russell Investments Group Ltd. acquired a new position in shares of Palvella Therapeutics during the third quarter valued at about $36,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Palvella Therapeutics in the 4th quarter valued at approximately $167,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Palvella Therapeutics in the 2nd quarter valued at approximately $37,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.